![The breaking news round-up: Decagear launches today, Pimax announces new headsets, and more! [APRIL FOOL’S]](https://i0.wp.com/skarredghost.com/wp-content/uploads/2025/03/lawk_glasses_handson.jpg?fit=1366%2C1025&ssl=1)
Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition
The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the product's usage, BMS said Monday post-market, a development that could considerably cap its sales ceiling. ...
The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the product's usage, BMS said Monday post-market, a development that could considerably cap its sales ceiling. ...
